Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Drug ventures target pain relief

February 20, 2006 | A version of this story appeared in Volume 84, Issue 8

Evotec and Apeiron Biologics will collaborate to develop small molecules targeting a novel therapeutic concept for pain relief. The concept is based on research activities of Josef Penninger, director of the Institute for Molecular Biotechnology of the Austrian Academy of Sciences. Apeiron Biologics and Evotec will jointly develop tailored biochemical and cellular assays. Evotec will apply its technology in using such assays for ultra-high-throughput screening to identify promising hit molecules. In a separate venture, BioXell and Lay Line Genomics have reached a license agreement for development of MNAC13, a novel humanized monoclonal antibody that blocks the action of nerve growth factor, a key mediator of pain. According to the agreement, BioXell will take MNAC13 through development and potential commercialization and pay LLG an undisclosed up-front sum, milestones, and royalties.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.